Healthy Adults
Conditions
Interventions
Oligonol1 g/day,10 cupsiles/day,4 weeks
Placebo (Dextrin), 10 capsules/day for 4 weeks
Sponsors
Amino Up Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Individuals with a BMI of 22.0 kg/m2 or higher but less than 30.0 kg/m2 2.Men and women aged 25 to 64 3.Individuals who have provided written consent to participate in this study
Exclusion criteria
Exclusion criteria: 1.Individuals for whom participation in the trial is difficult due to liver, kidney, or heart disease; respiratory disorders; endocrine disorders; metabolic disorders; neurological disorders; impaired consciousness; diabetes; or other medical conditions 2.Individuals who have undergone surgery or received medication for an illness or injury within two months prior to the start of this trial 3.Individuals currently taking medications to improve glucose metabolism, lipid metabolism, or blood pressure 4.Individuals who regularly consume foods for specific health uses or foods with functional claims (however, this does not apply to those who can suspend consumption during the trial period at the time of obtaining the consent form) 5.Individuals who are unable to consume the test food 6.Individuals who may exhibit allergic reactions to ingredients contained in the test food 7.Individuals currently participating in another clinical trial or planning to participate in one during the duration of this trial 8.Individuals who do not agree with the purpose of this trial as explained in the pre-trial briefing 9.Individuals who are pregnant or breastfeeding, or who plan to become pregnant or breastfeed during the trial period 10.Any other individuals whom the principal investigator deems unsuitable from the perspective of ensuring subject safety, based on data from health examinations or other sources
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse events | — |
Secondary
| Measure | Time frame |
|---|---|
| Physical examination, blood tests, urine tests | — |
Countries
Japan
Contacts
Public ContactShigenori Nibun
EAS inc. Clinical Trial Session
Outcome results
None listed